Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 26 references it cites were found in a registry or an index; 18 of the 33 sources its claims cite were checked for support.

Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders

Open access

Abstract

The 26S proteasome is a large, ATP-dependent proteolytic complex responsible for degrading ubiquitinated proteins in eukaryotic cells. It plays a crucial role in maintaining cellular protein homeostasis by selectively eliminating misfolded, damaged, or regulatory proteins marked for degradation. In this study, whole-exome sequencing (WES) was performed on an individual presenting with developmental delay and mild intellectual disability, as well as on both of his unaffected parents. This analysis identified a de novo variant, c.959C>G (p.Pro320Arg), in the PSMC5 gene. As predicted, this gene shows a very likely autosomal dominant inheritance pattern. Notably, PSMC5 has not previously been associated with any phenotype in the OMIM database. This variant was recently submitted to the ClinVar database as a variant of uncertain significance (VUS) and remains absent in both gnomAD and dbSNP. Notably, it has been identified in six unrelated individuals presenting with clinical features comparable to those observed in the patient described in this study. Multiple in silico prediction tools classified the variant as pathogenic, and a PhyloP conservation score supports strong evolutionary conservation of the mutated nucleotide. Protein structure predictions using the AlphaFold3 algorithm revealed notable structural differences between the mutant and wild-type PSMC5 proteins. We hypothesize that the p.Pro320Arg substitution alters the structure and function of PSMC5 as a regulatory subunit of the 26S proteasome, potentially impairing the stability and activity of the entire complex. Although functional studies are imperative, this study contributes to a deeper understanding of PSMC5, expands the spectrum of associated neurodevelopmental phenotypes, and highlights its potential as a therapeutic target. Furthermore, this study resulted in the submission of the identified variant to the ClinVar database (SCV006083352), where it was classified as pathogenic.

Overview

CoChat Summary

TL;DR

This case report used trio whole-exome sequencing to identify a de novo PSMC5 variant, c.959C>G (p.Pro320Arg), in a patient with global developmental delay and mild intellectual disability. In silico and AlphaFold3 analyses supported pathogenicity and predicted structural changes, but functional validation remains necessary.

Key findings

  • WES identified a de novo heterozygous PSMC5 variant, c.959C>G (p.Pro320Arg), absent in both unaffected parents and in gnomAD and dbSNP; the patient was diagnosed with global developmental delay (HP:0001263) and mild intellectual disability (HP:0001256).
  • The variant was classified as pathogenic by ACMG criteria, with a DOMINO autosomal dominant probability score of 0.981 and a PhyloP conservation score of 7.905; multiple in silico tools predicted pathogenic or strongly pathogenic effects (e.g., AlphaMissense 0.996, MetaRNN 0.977, REVEL 0.917).
  • AlphaFold3 comparison of wild-type and mutant PSMC5 showed 251/406 residues aligned with RMSD 0.333 Å, but all 406 residues had RMSD 7.645 Å; wild-type had 339 hydrogen bonds versus 337 in the mutant, with 23 wild-type-only and 21 mutant-only hydrogen bonds. Wild-type Pro320 bonded with Arg325, while mutant Arg320 bonded with Arg325 and Thr194.
  • The same p.Pro320Arg variant was previously identified in six unrelated individuals with neurodevelopmental disorders, including two DECIPHER de novo cases (IDs 306096 and 307251); PSMC5 was recently included in SFARI with a score of 3. The authors submitted the variant to ClinVar as SCV006083352, classified pathogenic.

Methods

  • Trio whole-exome sequencing was performed on the patient and both parents using the Agilent SureSelect V7 kit and Illumina HiSeq 3000, achieving at least 20× coverage for 97% of targeted regions; variants were filtered by inheritance pattern and MAF <1%, aligned to HG38, and validated by Sanger sequencing.
  • Variant classification used ACMG guidelines and VarSome; in silico prediction tools included BayesDel, MetaRNN, MetaSVM, REVEL, AlphaMissense, EIGEN, FATHMM-XF, Mutation assessor, MutPred, PrimateAI, PROVEAN, SIFT, and others.
  • Structural analysis used AlphaFold3 predictions for wild-type and mutant PSMC5, selecting the best model by highest plDDT (wild-type model 3 average 81.125; mutant model 3 average 80.396), visualized with UCSF ChimeraX 1.8; BrainRNA-Seq, BrainSpan, and Complex Portal/PDB 6msk were also used.

Limitations

  • The authors state that predicting the structural and functional consequences of Pro320Arg on the entire 26S proteasome is difficult; AlphaFold-Multimer analysis of the full complex was not performed because of the large number of subunits and computational resource requirements.
  • The authors state that they cannot rule out other genetic variants not detected by WES that may have contributed to the patient’s clinical presentation, and that functional studies are imperative to confirm the gene–disease association and validate the variant as a potential mutational hotspot.
  • The authors note that thyroid abnormalities were not reported in the six previously described individuals carrying the same variant, and they cannot conclusively attribute the patient’s thyroid abnormalities to the secondary FGFR1 variant c.2200C>T (p.Arg734Trp). Evident from the text: this is a single-patient case report with in silico structural predictions and no experimental functional validation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms26136386

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Chromosomal localization and next-generation sequencing (NGS) analysis identifying the c.959C>G (p.Pro320Arg) variant in the PSMC5 gene (NM_002805.6). (a) Schematic representation of the chromosomal localization of the PSMC5 gene, highlighting the identified variant within exon 9. (b) Integrative Genomics Viewer (IGV) snapshot showing the heterozygous c.959C>G variant in the patient, absent in both healthy parents, confirming its de novo origin.
Figure 1 Chromosomal localization and next-generation sequencing (NGS) analysis identifying the c.959C>G (p.Pro320Arg) variant in the PSMC5 gene (NM_002805.6). (a) Schematic representation of the chromosomal localization of the PSMC5 gene, highlighting the identified variant within exon 9. (b) Integrative Genomics Viewer (IGV) snapshot showing the heterozygous c.959C>G variant in the patient, absent in both healthy parents, confirming its de novo origin.CC BY · PubMed Central
Figure 2 Protein structure alignment performed with the two best predicted models of both the wild-type (red) and the mutated Pro320Arg PSMC5 proteins (blue). (a) Graphical representation of the superimposed structure alignment carried out using the best AlphaFold3 models for both the wild-type and the mutated Pro320Arg PSMC5. Superimposition was carried out using UCSF ChimeraX software version 1.8. (b) Depiction of the aligned amino acids resulting from the protein structure alignment. The root main standard deviation (RMSD) is indicated in the figure and is expressed in Angstroms (Å). Asterisk indicates the specific mutation site.
Figure 2 Protein structure alignment performed with the two best predicted models of both the wild-type (red) and the mutated Pro320Arg PSMC5 proteins (blue). (a) Graphical representation of the superimposed structure alignment carried out using the best AlphaFold3 models for both the wild-type and the mutated Pro320Arg PSMC5. Superimposition was carried out using UCSF ChimeraX software version 1.8. (b) Depiction of the aligned amino acids resulting from the protein structure alignment. The root main standard deviation (RMSD) is indicated in the figure and is expressed in Angstroms (Å). Asterisk indicates the specific mutation site.CC BY · PubMed Central
Figure 3 Structural comparison between the selected best models of the wild-type and Pro320Arg-mutated PSMC5 proteins based on AlphaFold3 predictions. (a) Predicted 3D model of the wild-type PSMC5 protein. The color gradient represents the amino acid sequence from the N-terminus (blue) to the C-terminus (red). The position of Pro320 is highlighted by both a black square and an arrow. (b) Close-up view of the wild-type Pro320 residue (magenta), showing a hydrogen bond with Arg325. (c) Predicted 3D model of the Pro320Arg-mutated PSMC5 protein, colored from the N-terminus (blue) to the C-terminus (red). The mutated Arg320 residue is indicated by a black square and arrow. (d) Close-up view of Arg320 (magenta) in the mutant protein, forming two hydrogen bonds with Arg325 and Thr194. All the protein models were generated using the AlphaFold3 server and visualized using UCSF ChimeraX version 1.8.
Figure 3 Structural comparison between the selected best models of the wild-type and Pro320Arg-mutated PSMC5 proteins based on AlphaFold3 predictions. (a) Predicted 3D model of the wild-type PSMC5 protein. The color gradient represents the amino acid sequence from the N-terminus (blue) to the C-terminus (red). The position of Pro320 is highlighted by both a black square and an arrow. (b) Close-up view of the wild-type Pro320 residue (magenta), showing a hydrogen bond with Arg325. (c) Predicted 3D model of the Pro320Arg-mutated PSMC5 protein, colored from the N-terminus (blue) to the C-terminus (red). The mutated Arg320 residue is indicated by a black square and arrow. (d) Close-up view of Arg320 (magenta) in the mutant protein, forming two hydrogen bonds with Arg325 and Thr194. All the protein models were generated using the AlphaFold3 server and visualized using UCSF ChimeraX version 1.8.CC BY · PubMed Central
Figure 4 Brain expression of PSMC5 across human brain structures. (a) Barplot illustrating PSMC5 expression levels, measured in fragments per kilobase of transcript per million mapped reads (FPKM), across various human brain cell types. Data were retrieved from the BrainRNA-Seq database. (b) Heatmap representing developmental expression patterns of PSMC5, measured in reads per kilobase of transcript per million mapped reads (RPKM), across multiple human brain regions at different developmental stages. Data were obtained from the BrainSpan database.
Figure 4 Brain expression of PSMC5 across human brain structures. (a) Barplot illustrating PSMC5 expression levels, measured in fragments per kilobase of transcript per million mapped reads (FPKM), across various human brain cell types. Data were retrieved from the BrainRNA-Seq database. (b) Heatmap representing developmental expression patterns of PSMC5, measured in reads per kilobase of transcript per million mapped reads (RPKM), across multiple human brain regions at different developmental stages. Data were obtained from the BrainSpan database.CC BY · PubMed Central
Figure 5 Structural depiction of the human 26S proteasome complex with a focus on the PSMC5 subunit. (a) Graphical representation of the 26S proteasome structure (PDB ID: 6MSK) deposited in the Protein Data Bank, with the PSMC5 subunit highlighted in red. (b) The predicted wild-type PSMC5 protein structure generated using the AlphaFold3 server is shown. Wild-type Pro320 is indicated by both the yellow square and the black arrow.
Figure 5 Structural depiction of the human 26S proteasome complex with a focus on the PSMC5 subunit. (a) Graphical representation of the 26S proteasome structure (PDB ID: 6MSK) deposited in the Protein Data Bank, with the PSMC5 subunit highlighted in red. (b) The predicted wild-type PSMC5 protein structure generated using the AlphaFold3 server is shown. Wild-type Pro320 is indicated by both the yellow square and the black arrow.CC BY · PubMed Central
Figure 6 Line plots illustrate the variations in predicted local distance difference test (plDDT) scores across the five AlphaFold3 models for both the wild-type and p.Pro320Arg-mutated PSMC5 proteins. (a) The plot shows plDDT values for the wild-type PSMC5 predictions, highlighting “Model 3” as the best-performing model, with an average plDDT score of 81.125. (b) Similarly, the plot displays plDDT variations for the mutated p.Pro320Arg PSMC5 protein, where “Model 3” also emerged as the best model, with an average plDDT score of 80.396.
Figure 6 Line plots illustrate the variations in predicted local distance difference test (plDDT) scores across the five AlphaFold3 models for both the wild-type and p.Pro320Arg-mutated PSMC5 proteins. (a) The plot shows plDDT values for the wild-type PSMC5 predictions, highlighting “Model 3” as the best-performing model, with an average plDDT score of 81.125. (b) Similarly, the plot displays plDDT variations for the mutated p.Pro320Arg PSMC5 protein, where “Model 3” also emerged as the best model, with an average plDDT score of 80.396.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 0 Not valid · 12 Not checked · 39 Own results and interpretations

31 more claims · 1 with their cited sources checked

Create a free account to see all 65 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 14
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 26 references

Cited by

See all 2

Metadata

Authors
Vinci, M., Musumeci, A., Papa, C., Ragalmuto, A., Saccone, S., Federico, C., Greco, D., Greco, V., Calì, F., & Treccarichi, S.
Affiliations
  • I.R.C.C.S. Oasi Maria SS (IT)
  • University of Catania (IT)
  • Oasi Research Institute-IRCCS, 94018 Troina, Italy
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2025-07-02
Volume
26
Issue
13
Pages
6386
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4411973343
Cited by
2
References
26
Citations by year
2025: 2
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Italian Ministry of Health “Ricerca Corrente 2017–2023”
  • 5xmille
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
26S proteasome, de novo mutations, intellectual disability, developmental delay, neurodevelopmental disorders, variants of uncertain significance, autosomal dominant inheritance, protein structure prediction, AlphaFold3, pathogenicity prediction
MeSH terms
Exome Sequencing, Humans, Intellectual Disability, Mutation, Pedigree, Genetic Predisposition to Disease, Proteasome Endopeptidase Complex, Neurodevelopmental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders. https://app.cochat.ai/papers/10.3390/ijms26136386
The paper
Vinci, M., Musumeci, A., Papa, C., Ragalmuto, A., Saccone, S., Federico, C., Greco, D., Greco, V., Calì, F., & Treccarichi, S. (2025). Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136386

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.